High-Risk Human Papillomavirus Messenger RNA Testing Using Urine, Cervicovaginal Self-Collected and Provider-Collected Cervical Samples Among Women in Mombasa, Kenya

Author image
ICRHK
Research publications

Brigid K Grabert 1, Jessica Y Islam 2, Michael Mutua, Emmanuel Kabare, Griffins Manguro, Wairimu Waweru, Kishor Mandaliya 3, Juma Shafi, R Scott McClelland, Jennifer S Smith

Affiliations

  • 1From the Lineberger Cancer Center, University of North Carolina at Chapel Hill, NC.
  • 2Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • 3Pathcare Laboratories, Mombasa, Kenya.

PMID: 35195617 PMCID: PMC9392816 (available on ) DOI: 10.1097/OLQ.0000000000001619

Abstract

We compared human papillomavirus messenger RNA testing using urine, self-, and provider-collected samples for the detection of high-grade cervical cytology and assessed acceptability of urine self-collection among females who engage in sex work in Kenya. Participants found urine sampling comfortable, but high-risk human papillomavirus messenger RNA detection in urine samples was less likely to detect high-grade lesions than self- and provider-collected cervical samples.

Conflict of interest statement

Conflict of Interest and Sources of Funding: J.S.S. has received unrestricted educational grants, consultancy, and research grants from Merck Corporation and GlaxoSmithKline over the past 5 years. R.S.M. has received honoraria for consulting from Lupin Pharmaceuticals and research funding, paid to the University of Washington, from Hologic Corporation. All other authors have no conflicts to declare.

Link

https://pubmed.ncbi.nlm.nih.gov/35195617/

 

Tags :
Share This Post